First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma

First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma

Abstract Radiotheranostics using somatostatin receptor (SSTR)-targeted agents has transformed the management of neuroendocrine tumors, yet its application in other oncological entities remains unexplored. Here, we report the first-in-human use of [177Lu]Lu-DOTATATE in two patients with advanced, tri...

Full description

Saved in:
Bibliographic Details
Main Authors: Wendy Delbart, Marie Vercruyssen, Rachele Danieli, Clémentine Marin, Zéna Wimana, Nathalie Meuleman, Patrick Flamen, Erwin Woff, Ioannis Karfis
Format: Article
Language:English
Published: Springer 2025-07-01
Series:EJNMMI Reports
Subjects:
Peptide receptor radionuclide therapy
[177Lu]Lu-DOTATATE
Radiotheranostics
Somatostatin receptors
Multiple myeloma
Online Access:https://doi.org/10.1186/s41824-025-00262-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41824-025-00262-8

Similar Items